Can-Fite BioPharma Ltd. (NYSE MKT: CANF) is an advanced clinical stage drug development company with a platform technology that is designed to address the treatment of cancer and inflammatory diseases. The company’s CF101 is in Phase II/III trials for the treatment of psoriasis. CF102, the company’s liver cancer drug, is commencing Phase II trials and has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. For more information, visit the company’s website at www.canfite.com.

Noble Financial Capital Markets, an equity research driven, full-service, investment banking boutique, is hosting its tenth annual equity conference in Sandpiper Bay, FL. Attended by institutional investors from across North America, the event features more than 140 public company executive teams from a diverse range of industries. For more information, visit www.noble.missionir.com.